871
Views
11
CrossRef citations to date
0
Altmetric
Original Article

Cardiac replacement therapies: outcomes and costs for heart transplantation versus circulatory assist

, , , , , & show all
Pages 1-7 | Received 07 Sep 2015, Accepted 25 May 2016, Published online: 20 Jun 2016

References

  • Rathi S, Deedwania PC. The epidemiology and pathophysiology of heart failure. Med Clin North Am. 2012;96:881–890.
  • Stehlik J, Edwards LB, Kucheryavaya AY, et al. The registry of the international society for heart and lung transplantation: twenty-seventh official adult heart transplant report. J Heart Lung Transplant. 2010;29:1089–1103.
  • Sauer CM, Yuh DD, Bonde P. Extracorporeal membrane oxygenation use has increased by 433% in adults in the United States from 2006 to 2011. Asaio J. 2015;61:31–36.
  • Stretch R, Sauer CM, Yuh DD, et al. National trends in the utilization of short-term mechanical circulatory support: incidence, outcomes, and cost analysis. J Am Coll Cardiol. 2014;64:1407–1415.
  • Moskowitz AJ, Rose EA, Gelijns AC. The cost of long-term LVAD implantation. Ann Thorac Surg. 2001;71:S195–S198.
  • Beyersdorf F. Economics of ventricular assist devices: European view. Ann Thorac Surg. 2001;71:S192–S194.
  • Clarke A, Pulikottil-Jacob R, Connock M, et al. Cost-effectiveness of left ventricular assist devices (LVADs) for patients with advanced heart failure: analysis of the British NHS bridge to transplant (BTT) program. Int J Cardiol. 2014;171:338–345.
  • Stehlik J, Stevenson LW, Edwards LB, et al. Organ allocation around the world: insights from the ISHLT international registry for heart and lung transplantation. J Heart Lung Transplant. 2014;33:975–984.
  • Owens AT, Jessup M. Should left ventricular assist device be standard of care for patients with refractory heart failure who are not transplantation candidates?: left ventricular assist devices should not be standard of care for transplantation-ineligible patients. Circulation. 2012;126:3088–3094.
  • Mishra V, Geiran O, Fiane AE, et al. Costs and reimbursement gaps after implementation of third-generation left ventricular assist devices. J Heart Lung Transplant. 2010;29:72–78.
  • Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–2251.
  • Petrucci RJ, Wright S, Naka Y, et al. Neurocognitive assessments in advanced heart failure patients receiving continuous-flow left ventricular assist devices. J Heart Lung Transplant. 2009;28:542–549.
  • Kamouh A, John R, Eckman P. Successful treatment of early thrombosis of HeartWare left ventricular assist device with intraventricular thrombolytics. Ann Thorac Surg. 2012;94:281–283.
  • Topkara VK, Kondareddy S, Malik F, et al. Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era. Ann Thorac Surg. 2010;90:1270–1277.
  • Frazier OH, Rose EA, Oz MC, et al. Multicenter clinical evaluation of the heartmate; vented electric left ventricular assist system in patients awaiting heart transplantation. J Heart Lung Transplant. 2001;20:201–202.
  • Kirklin JK, Naftel DC, Pagani FD, et al. Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation? J Thorac Cardiovasc Surg. 2012;144:584–603.
  • Droogne W, Jacobs S, Van den Bossche K, et al. Cost of 1-year left ventricular assist device destination therapy in chronic heart failure: a comparison with heart transplantation. Acta Clin Belg. 2014;69:165–170.
  • Kirklin JK, Mehra MR. The dawn of the ISHLT mechanical assisted circulatory support (IMACS) registry: fulfilling our mission. J Heart Lung Transplant. 2012;31:115–116.
  • Vanden Eynden F, Antoine M, El Oumeiri B, et al. How to cope with a temporarily aborted transplant program: solutions for a prolonged waiting period. Ann Transl Med. 2015;3:306.
  • Pulikottil-Jacob R, Suri G, Connock M, et al. Comparative cost-effectiveness of the HeartWare versus HeartMate II left ventricular assist devices used in the United Kingdom National health service bridge-to-transplant program for patients with heart failure. J Heart Lung Transplant. 2014;33:350–358.
  • Karason K, Dellgren G, Redfors B, et al. Left Ventricular Assist Device as permanent support in patients with terminal heart failure. Göteborg: Västra Götalandsregionen, Sahlgrenska Universitetssjukhuset, HTA-centrum; 2014. Regional activity-based HTA 2014:66
  • Digiorgi PL, Reel MS, Thornton B, et al. Heart transplant and left ventricular assist device costs. J Heart Lung Transplant. 2005;24:200–204.
  • Mulloy DP, Bhamidipati CM, Stone ML, et al. Orthotopic heart transplant versus left ventricular assist device: a national comparison of cost and survival. J Thoracic Cardiovasc Surg. 2013;145:566–573.
  • Maxwell BG, Powers AJ, Sheikh AY, et al. Resource use trends in extracorporeal membrane oxygenation in adults: an analysis of the Nationwide inpatient sample 1998-2009. J Thorac Cardiovasc Surg. 2014;148:416–421.
  • Gjesdal O, Gude E, Arora S, et al. Intra-aortic balloon counterpulsation as a bridge to heart transplantation does not impair long-term survival. Eur J Heart Fail. 2009;11:709–714.
  • Lahpor J, Khaghani A, Hetzer R, et al. European results with a continuous-flow ventricular assist device for advanced heart-failure patients. Eur J Cardiothorac Surg. 2010;37:357–361.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.